Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lonza will initiate new autologous virally-transfected T-cell product manufacturing in new cGMP viral immunotherapy manufacturing suites in Houston, Texas, US.
Subscribe to our email newsletter
Lonza completed validation of viral-induced cell processing GMP suites and completed the tech transfer process.
Lonza viral-based therapeutics head David Enloe said, "We are pleased to have been selected by our existing viral vector client to additionally perform the development and manufacture of virally-modified cellular products to support its clinical studies."
The company previously expanded the GMP facilities in Houston to add various cell processing suites.